James Rhee, MD
Pain Medicine · Stanford, CANPI 1629074364
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $856 of the $1,364 with a category attached, or 62.8%. Pacira Pharmaceuticals Incorporated accounts for 86.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $1,175 and has fallen 90.3% since, to $114 in 2025. That places this record below the midpoint for pain medicine clinicians in CA, where the typical reported total is $1,829.
Across 10 payments — averaging $136.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$1K
- Boston Scientific$114
- SPR Therapeutics, Inc$59
- Abbott$16
What the payments were for
- Travel & lodging$85663%
- Food & beverage$50837%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 7 | $1,175 |
| Boston Scientific | 1 | $114 |
| SPR Therapeutics, Inc | 1 | $59 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,364 in reported general payments places this provider in the 45th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 40 | $1,742 |
| Gabapentin | 119 | $1,198 |
| Etodolac | 39 | $913 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 11 | $857 |
| Pregabalin | 22 | $484 |
| Methylprednisolone | 67 | $462 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 61 | $446 |
| Duloxetine Hcl | 14 | $385 |
| Meloxicam | 75 | $347 |
| Cyclobenzaprine Hcl | 20 | $296 |
| Methocarbamol | 21 | $240 |
| Ibuprofen | 14 | $164 |
| Diclofenac Sodium | 14 | $108 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $82 |
| Lorazepam | 30 | $38 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Stanford
- Einar OttestadStanford$352K
- Robert CowanStanford$124K
- Vafi SalmasiStanford$55K
- Jennifer HahStanford$39K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.